Fucoidan
Based on 8 publication(s) in Google Scholar
Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 9072-19-9
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Marine-Sourced Natural Product Library
HY-L143
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Polysaccharides Compound Library
HY-L216
-
Cosmetic Ingredient Compound Library
HY-L221
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) Fucoidan
More- Adv Mater. 2026 Feb;38(11):e11078. [Abstract]
- Nat Biomed Eng. 2026 Jun 3. [Abstract]
- Adv Funct Mater. 2025 Nov 4.
- J Transl Med. 2024 Feb 15;22(1):155. [Abstract]
- J Colloid Interface Sci. 2025 Jun 30;700(Pt 1):138290. [Abstract]
- Int J Biol Macromol. 2026 May:361:152014. [Abstract]
- CNS Neurosci Ther. 2024 Aug;30(8):e14903. [Abstract]
- J Biochem Mol Toxicol. 2025 Nov;39(11):e70574. [Abstract]
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
WB
-
Histological Imaging/Staining
-
Histological Imaging/Staining
Activité biologique
Fucoidan is a biologically active polysaccharide found in great abundance in brown marine algae[1].
Fucoidan extracted from A. nodosum is a more potent inhibitor of α-glucosidase, with an IC50 ranging from 0.013 to 0.047 mg/mL, than the inhibition by Fucoidan extracted from F. vesiculosus (IC50=0.049 mg/mL). Fucoidan extracted from F. vesiculosus does not inhibit α-amylase activity, while Fucoidan from A. nodosum decreases α-amylase activity by 7-100% at 5 mg/mL depending upon the algae harvest period. Fucoidan from A. nodosum inhibits α-amylase with an IC50 of 0.12-4.64 mg/mL[1].
Fucoidan is a fucose-rich sulfated polysaccharide typically found in the cell wall of marine algae but also recently isolated from terrestrial sources. Fucoidan exhibits an attractive therapeutic potential against a wide array of metabolic diseases associated with oxidative stress[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice[3]
-
Dosage:10-400 mg/kg
-
Administration:Intraperitoneal injection; followed by total-body irradiation
-
Result:The mice injected with 100 mg/kg showed the best survival rate at 30 days post-irradiation.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 9072-19-9
-
Appearance Solid
-
Color Off-white to light brown
-
SMILES
[Fucoidan]
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Adv Mater
Fluoropolymer-Mediated Delivery of a Dual TSHR/IGF1R-Targeting CRISPR-Cas9 System for Localized Therapy in Thyroid-Associated Ophthalmopathy. [Abstract]2026 Feb;38(11):e11078. PMID: 41486850 -
Nat Biomed Eng
Modular nucleic acid-based construct for delivery of immunostimulatory agonists and oncogene-silencing oligonucleotides in tumours. [Abstract]2026 Jun 3. PMID: 42236980 -
-
J Transl Med
Fucoidan modulates SIRT1 and NLRP3 to alleviate hypertensive retinopathy: in vivo and in vitro insights. [Abstract]2024 Feb 15;22(1):155. PMID: 38360728
Fucoidan purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Feb 15;22(1):155. [Abstract]
mRECs were treated with with Fucoidan (FO, 60 μg/ml) for an additional 4 h, and then treated with Ang II (100 nM) for 24 h. 2′,7′-Dichlorodihydrofluorescein diacetate (DCFH-DA) staining of ROS production in cells (left), the quantification of ROS intensity.
Fucoidan purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Feb 15;22(1):155. [Abstract]
mRECs were treated with with Fucoidan (FO, 60 μg/ml) for an additional 4 h, and then treated with Ang II (100 nM) for 24 h. qPCR analyses of Sirt1, Nlrp3 and Il1b mRNA in mRECs.
Fucoidan purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Feb 15;22(1):155. [Abstract]
mRECs were treated with with Fucoidan (FO, 60 μg/ml) for an additional 4 h, and then treated with Ang II (100 nM) for 24 h. The expression of SIRT1, NLRP3, IL-1β and IL-1β p17 protein levels.
Fucoidan purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Feb 15;22(1):155. [Abstract]
We gave the mice with Fucoidan (300 mg/kg/day) one day before Ang II infusion. H&E staining showed that Fucoidan treatment decreased Ang II-induced central retinal thickening.
Fucoidan purchased from MedChemExpress. Usage Cited in: J Transl Med. 2024 Feb 15;22(1):155. [Abstract]
Mice were treated with Fucoidan (300 mg/kg/day) one day before Ang II perfusion, followed by once daily for 3 weeks. Retinal angiography and fundus photography were performed.
-
J Colloid Interface Sci
Platelet-hitchhiking triiodothyronine nanoparticles for enhanced therapy of cerebral ischemia-reperfusion injury. [Abstract]2025 Jun 30;700(Pt 1):138290. PMID: 40618479 -
Int J Biol Macromol
A vascular graft with hydrogen-bonded network structure for leak-free puncture resistance, spatiotemporal anticoagulation, and rapid endothelialization via fucoidan-heparin functionalization. [Abstract]2026 May:361:152014. PMID: 41997327 -
CNS Neurosci Ther
Fucoidan improving spinal cord injury recovery: Modulating microenvironment and promoting remyelination. [Abstract]2024 Aug;30(8):e14903. PMID: 39139089 -
J Biochem Mol Toxicol
Fucoidan Prevents Paraquat-Induced Hepatic Injury by Attenuating Oxidative and Inflammatory Stress: An In Vivo and In Vitro Approach. [Abstract]2025 Nov;39(11):e70574. PMID: 41158090
Solvant et solubilité
H2O : 5 mg/mL (ultrasonic and warming and heat to 60°C)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 5 mg/mL; Clear solution; Need ultrasonic and warming and heat to 60°C
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kyung-Tae Kim, et al. Alpha-amylase and alpha-glucosidase inhibition is differentially modulated by fucoidan obtained from Fucus vesiculosus and Ascophyllum nodosum.Phytochemistry. 2014 Feb;98:27-33. [Content Brief]
[2]. Zeinab El Rashed, et al. Antioxidant and Antisteatotic Activities of Fucoidan Fractions from Marine and Terrestrial Sources. Molecules. 2021 Jul 24;26(15):4467. [Content Brief]
[3]. Farzaneh Atashrazm, et al. Fucoidan and cancer: a multifunctional molecule with anti-tumor potential. Mar Drugs. 2015 Apr 14;13(4):2327-46. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fucoidan Related Classifications
HY-132179 Related Classifications
Powered by Bioz